FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011191678> ?p ?o ?g. }

• W2011191678 endingPage "676" @default.
• W2011191678 startingPage "667" @default.
• W2011191678 abstract "Optimal treatment of human immunodeficiency virus (HIV)-associated non-Hodgkin lymphoma (NHL) has yet to be defined, because chemotherapy could exacerbate immunodeficiency, with subsequent adverse effects for patients.The authors investigated the feasibility of an intensive chemotherapy regimen for HIV-associated NHL. Thirty-eight patients were treated with a first course of cyclophosphamide (Cy), vincristine, and prednisone; followed by 3 courses of high-dose Cy (2000 mg/m2), doxorubicin (Doxo; 50 mg/m2), vincristine, and prednisone (modified high-dose CHOP); 1 course of high-dose methotrexate (MTX; 8000 mg/m2); and 1 course of high-dose cytarabine (8000 mg/m2). Radiotherapy was added to the treatment regimen for patients with bulky disease or residual tumor. Chemotherapy was administered in conjunction with granulocyte-colony-stimulating factor and antiretroviral therapy.Patients received 91.5%, 93%, 66%, and 63% of the scheduled doses of Cy, Doxo, MTX, and cytarabine, respectively. The complete response rate was 60.5%, with a total response rate of 79%. The 40-month overall survival rate was 43%, the disease-free survival rate was 65%, and the recurrence-free survival rate was 39%. Both an International Prognostic Index score of 0 or 1 and Burkitt-type histology had positive effects on survival, whereas CD4-positive lymphocyte counts, viral burden, and previous highly active antiretroviral therapy did not. CD4-positive T lymphocyte levels decreased from 0.197 +/- 0.156 x10(9)/L before treatment to 0.152 +/- 0.1 x10(9)/L at 6 months after the end of treatment. A decrease in viral load, from 380,000 +/- 785,000 copies/mL before treatment to 25,000 +/- 43,000 copies/mL at 6 months after the end of treatment, also was observed.The results of the current study indicate that intensive chemotherapy is effective and tolerable for patients with HIV-associated NHL." @default.
• W2011191678 created "2016-06-24" @default.
• W2011191678 creator A5000969643 @default.
• W2011191678 creator A5016240673 @default.
• W2011191678 creator A5019889051 @default.
• W2011191678 creator A5021314773 @default.
• W2011191678 creator A5029679351 @default.
• W2011191678 creator A5044335760 @default.
• W2011191678 creator A5044899765 @default.
• W2011191678 creator A5047798037 @default.
• W2011191678 creator A5058362193 @default.
• W2011191678 creator A5079928258 @default.
• W2011191678 creator A5081349811 @default.
• W2011191678 creator A5081353121 @default.
• W2011191678 creator A5090987375 @default.
• W2011191678 date "2004-01-01" @default.
• W2011191678 modified "2023-10-17" @default.
• W2011191678 title "Intensive sequential chemotherapy with hematopoietic growth factor support for non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus" @default.
• W2011191678 cites W105359055 @default.
• W2011191678 cites W135413908 @default.
• W2011191678 cites W1618865275 @default.
• W2011191678 cites W1757115607 @default.
• W2011191678 cites W1875822544 @default.
• W2011191678 cites W1896652710 @default.
• W2011191678 cites W1918969113 @default.
• W2011191678 cites W1933587402 @default.
• W2011191678 cites W1946151534 @default.
• W2011191678 cites W1960823558 @default.
• W2011191678 cites W1971397057 @default.
• W2011191678 cites W1981798441 @default.
• W2011191678 cites W2006377199 @default.
• W2011191678 cites W2010848952 @default.
• W2011191678 cites W2022519258 @default.
• W2011191678 cites W2039104712 @default.
• W2011191678 cites W2042506860 @default.
• W2011191678 cites W2070128268 @default.
• W2011191678 cites W2089639116 @default.
• W2011191678 cites W2101080301 @default.
• W2011191678 cites W2118221216 @default.
• W2011191678 cites W2130904233 @default.
• W2011191678 cites W2132743254 @default.
• W2011191678 cites W2155306325 @default.
• W2011191678 cites W2169329856 @default.
• W2011191678 cites W2174167667 @default.
• W2011191678 cites W2179281499 @default.
• W2011191678 cites W2258868118 @default.
• W2011191678 cites W2307541432 @default.
• W2011191678 cites W2318621273 @default.
• W2011191678 cites W2318772898 @default.
• W2011191678 cites W2328003865 @default.
• W2011191678 cites W2328637330 @default.
• W2011191678 cites W2334839582 @default.
• W2011191678 cites W2334996101 @default.
• W2011191678 cites W2335295875 @default.
• W2011191678 cites W2339381415 @default.
• W2011191678 doi "https://doi.org/10.1002/cncr.20019" @default.
• W2011191678 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14770420" @default.
• W2011191678 hasPublicationYear "2004" @default.
• W2011191678 type Work @default.
• W2011191678 sameAs 2011191678 @default.
• W2011191678 citedByCount "12" @default.
• W2011191678 countsByYear W20111916782012 @default.
• W2011191678 countsByYear W20111916782014 @default.
• W2011191678 countsByYear W20111916782016 @default.
• W2011191678 crossrefType "journal-article" @default.
• W2011191678 hasAuthorship W2011191678A5000969643 @default.
• W2011191678 hasAuthorship W2011191678A5016240673 @default.
• W2011191678 hasAuthorship W2011191678A5019889051 @default.
• W2011191678 hasAuthorship W2011191678A5021314773 @default.
• W2011191678 hasAuthorship W2011191678A5029679351 @default.
• W2011191678 hasAuthorship W2011191678A5044335760 @default.
• W2011191678 hasAuthorship W2011191678A5044899765 @default.
• W2011191678 hasAuthorship W2011191678A5047798037 @default.
• W2011191678 hasAuthorship W2011191678A5058362193 @default.
• W2011191678 hasAuthorship W2011191678A5079928258 @default.
• W2011191678 hasAuthorship W2011191678A5081349811 @default.
• W2011191678 hasAuthorship W2011191678A5081353121 @default.
• W2011191678 hasAuthorship W2011191678A5090987375 @default.
• W2011191678 hasBestOaLocation W20111916781 @default.
• W2011191678 hasConcept C126322002 @default.
• W2011191678 hasConcept C141071460 @default.
• W2011191678 hasConcept C143998085 @default.
• W2011191678 hasConcept C203014093 @default.
• W2011191678 hasConcept C2776694085 @default.
• W2011191678 hasConcept C2776755627 @default.
• W2011191678 hasConcept C2778041864 @default.
• W2011191678 hasConcept C2778336483 @default.
• W2011191678 hasConcept C2778720950 @default.
• W2011191678 hasConcept C2779338263 @default.
• W2011191678 hasConcept C2779429289 @default.
• W2011191678 hasConcept C2781413609 @default.
• W2011191678 hasConcept C71924100 @default.
• W2011191678 hasConcept C90924648 @default.
• W2011191678 hasConceptScore W2011191678C126322002 @default.
• W2011191678 hasConceptScore W2011191678C141071460 @default.
• W2011191678 hasConceptScore W2011191678C143998085 @default.
• W2011191678 hasConceptScore W2011191678C203014093 @default.
• W2011191678 hasConceptScore W2011191678C2776694085 @default.

• next